Table 3 Comparison of treatments and outcomes between survivors and non-survivors
Total | Survivors | Non-survivors | P | |
|---|---|---|---|---|
n = 42 (%) | n = 34 (81%) | n = 8 (19%) | ||
ECMO types | 0.001* | |||
VV | 29 (69) | 28 (66.7) | 1 (2.4) | |
Other types | 13 (31) | 6 (14.3) | 7 (16.7) | |
Anticoagulation | 0.655 | |||
Heparin | 11 (26.2) | 9 (21.4) | 2 (4.8) | |
Nafamostat mesilate | 31 (73.8) | 25 (59.5) | 6 (14.3) | |
ECMO time (hours), median (IQR) | 155 (90.5–232.5) | 160 (114.0–240.7) | 24 (4.0–132.0) | 0.021* |
CRRT | 24 (57.1) | 19 (45.2) | 5 (11.9) | 0.527 |
Transfusion (U/day) during ECMO period, median (IQR) | ||||
Packed RBC | 1 (0.5–2.6) | 0.7 (0.4–1.7) | 5.7 (1.6–59.2) | 0.001* |
Fresh frozen plasma | 0.2 (0–1.3) | 0.2 (0–0.7) | 4.7 (0.9–29.3) | 0.001* |
Platelet concentrate | 0.1 (0–2.3) | 0 (0–1.4) | 7 (0–11.5) | 0.001* |
Cryoprecipitate | 0.0 (0–0) | 0.0 (0–0) | 0 (0–2.9) | 0.09 |
ICU stay (days), median (IQR) | 16 (7.7–24.2) | 17.5 (9.7–25.7) | 3 (1.0–8.5) | 0.014* |
Hospital stay (days), median (IQR) | 23 (13.2–51.2) | 28 (18–58.5) | 3 (1.0–8.5) | 0.006* |